Silence Therapeutics is led by a strong senior management team with a proven track record in drug development and successful team leadership.


Chief Executive

Ali joined Silence in August 2012 as director of corporate strategy and became Chief Executive in May 2013. He has over 17 years’ experience in the City and financial services, having started his career as a technology analyst at Duncan Lawrie, before moving to Credit Lyonnais Securities. In 2001, he co-founded Evolution Securities and ran the principal trading and market making arm. Ali has extensive experience in small companies and has held significant stakes in UK listed technology/biotech ventures.


Finance Director and Company Secretary

Timothy joined Silence in August 2012. Previously he was head of research at Xcap Securities, having also been an analyst at Evolution Securities. After qualifying as a chartered accountant he left accountancy to become a journalist. For twelve years he worked on the Daily Mail’s City and Finance desk, covering biotech, electronics and real estate.


Chief Scientific Officer

Jorg has more than 18 years’ experience in the biotechnology industry, in both the United States and Europe. Since joining Silence in 2000, he has served as both senior and associate director of technologies and now leads the Company’s research team in Berlin. Prior to joining Silence, Jorg was a senior scientist at Chiron Corporation, where he was responsible for leading a molecular biology research group focused on breast cancer.

From 1996-1997 he served as a group leader at the Institute of Tumour Biology (IMT) in Marburg, Germany, having previously been a postdoctoral fellow at the Howard Hughes Medical Institute at the University of California in Los Angeles. He received his Ph.D. in molecular biology from the Philipps University, Marburg.


Chief Medical Officer

Mike is a consultant physician and the Director of the Lipid and Coronary Prevention Clinics for Warwickshire, having previously been the Head of Molecular Medicine at the University of Warwick. He is an expert advisor to the UK Clinical Guidelines Development Group and The National Institute for Clinical Excellence (NICE), and has served on numerous advisory boards for pharmaceutical companies.

Mike is a highly cited researcher and experienced clinician with a long track record in metabolic medicine and cancer biology research as well as in the running of clinical trials. He has written several books on diabetes, cholesterol problems and cancer biology and teaches postgraduates and undergraduates in medicine and biological sciences. He has contributed to furthering the understanding of cancer cell biology and diabetes and along with colleagues is currently working on identifying novel tissue-based biomarkers for colorectal cancer and the development of novel diagnostic tools. Mike is a fellow of the Royal College of Physicians of London and a member of the Association of Physicians, HEART UK and Diabetes UK.